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Abstract
Dementia with Lewy bodies (DLB) and Parkinson’s Disease (PD) are common causes of motor and cognitive deficits and are
associated with the abnormal accumulation of alpha-synuclein (a-syn). This study investigated whether passive
immunization with a novel monoclonal a-syn antibody (9E4) against the C-terminus (CT) of a-syn was able to cross into
the CNS and ameliorate the deficits associated with a-syn accumulation. In this study we demonstrate that 9E4 was effective
at reducing behavioral deficits in the water maze, moreover, immunization with 9E4 reduced the accumulation of calpaincleaved a-syn in axons and synapses and the associated neurodegenerative deficits. In vivo studies demonstrated that 9E4
traffics into the CNS, binds to cells that display a-syn accumulation and promotes a-syn clearance via the lysosomal
pathway. These results suggest that passive immunization with monoclonal antibodies against the CT of a-syn may be of
therapeutic relevance in patients with PD and DLB.
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However, neurodegenerative processes in LBD are more
widespread than originally suspected [16] therefore there is a
need for therapeutic approaches that target toxic a-syn in multiple
neuronal populations simultaneously. For this reason we began to
explore an immunotherapy approach for LBD and have
previously shown that active immunization with recombinant asyn ameliorates a-syn related synaptic pathology in a transgenic
(tg) mouse model of PD [17]. Previous studies have shown that
intracellular antibodies (intrabodies) can inhibit a-syn aggregation
[18,19] and that copolymer-1 immunotherapy reduces neurodegeneration in a PD model [20].
The mechanisms through which a-syn immunotherapy might
work are unclear given that native a-syn is cytoplasmic. However,
it is possible that antibodies may recognize abnormal a-syn
accumulating in the neuronal plasma membrane [10,17,21,22] or
secreted forms of a-syn. In support of this possibility, studies have
shown that oligomerized a-syn is secreted in vitro [23] and in vivo
[24] via exocytosis, contributing to the propagation of the
synucleinopathy. Moreover, a-syn is present in the cerebrospinal
fluid of a-syn tg mice and in patients with LBD [25,26].
This study examined whether passive immunization with an
antibody against the C-terminus (CT) of a-syn (hereafter referred

Introduction
Neurodegenerative conditions with accumulation of a-synuclein
(a-syn) are common causes of dementia and movement disorders
in the aging population. Disorders where the clinical and
pathological features of Alzheimer’s Disease (AD) and Parkinson’s
Disease (PD) overlap are known as Lewy body disease (LBD) [1].
a-Syn is a natively unfolded protein [2] found at the presynaptic
terminal [3] and may play a role in synaptic plasticity [4].
Abnormal a-syn accumulation in synaptic terminals and axons
plays an important role in LBD [5,6,7,8]. Recent work has
suggested that a-syn oligomers rather than fibrils might be the
neurotoxic species [9,10].
While in rare familial cases mutations in a-syn might contribute
to oligomerization [11], it is unclear what triggers a-syn
aggregation in sporadic forms of LBD. Alterations in a-syn
synthesis, aggregation or clearance have been proposed to impact
the formation of toxic oligomers [12,13,14]. Therefore, strategies
directed at promoting the clearance of oligomers may be of
therapeutic value for LBD. Previous studies have used gene
therapy targeting selective regions to increase a-syn clearance via
autophagy or by reducing a-syn synthesis [12,15].
PLoS ONE | www.plosone.org
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to as the 9E4 antibody) was able to recognize and clear a-syn
aggregates in a-syn tg mice. We show that the 9E4 antibody
crossed into the CNS and ameliorated behavioral deficits and
neuropathological alterations in a-syn transgenic mice. In addition
we show that 9E4 is able to reduce the accumulation of calpaincleaved and oligomerized a-syn aggregates. These results imply
that passive immunization against the CT of a-syn may be an
important therapeutic alternative in patients with PD and DLB.

approved the experimental protocol (S02221) followed in all
studies according to the Association for Assessment and Accreditation of Laboratory Animal Care International guidelines.

Preparation of antibodies for passive immunization
Previous active immunization experiments have suggested that
the most effective antibodies were against CT-epitopes of a-syn
[17], for this study a panel of antibodies were developed 1) clone
8A5 (a-syn epitope 125–140; IgG1); 2) clone 9E4 (a-syn epitope
118–126; IgG1) and 6H7 (a-syn epitope 1–4: IgG1) (Table 1). The
9E4 and 6H7 antibodies were prepared by immunizing with
recombinant human a-syn, while 8A5 was generated with purified
bovine a-syn. Epitope mapping was done on 15-mer peptides that
had a 3 amino acid difference (i.e. 1–15, 3–18, etc, which gave an
epitope resolution of +/22 amino acids). For control experiments
a non-immune IgG1 (clone 27-1) prepared under similar
conditions was used. Initial immunoblot and immunohistochemical examination using these antibodies on untreated non-tg and asyn tg mice demonstrated that the 9E4 displayed the most
specificity for human a-syn therefore this antibody was chosen for
the immunization study.

Materials and Methods
Transgenic mouse model and passive immunization
For this study mice over-expressing a-syn under the PDGF-b
promoter (Line D) were utilized [27,28]. This model was selected
because mice from this line develop a-syn aggregates distributed
through the temporal cortex and hippocampus similar to what has
been described in LBD accompanied by behavioral deficits
[29,30].
Initial immunoblot and immunohistochemical studies were
conducted with a panel of antibodies directed at both N-terminus
(NT) (6H7) and CT-a-syn (8A5, 9E4) to determine which of these
antibodies displayed the most specific binding to human a-syn, of
these antibodies, 9E4 displayed the most specificity and was
chosen for the immunization study. A total of 40 a-syn tg mice (6
m/o, n = 20 mice per group) received weekly intraperitoneal (IP)
injections (10 mg/kg) for 6 months with the CT-a-syn antibody
(9E4) and IgG1 control. An additional group of non-tg mice
treated with the 9E4 antibody (n = 12) and the IgG1 control
(n = 12) was included as control for behavioral and neuropathological studies. Mice were bled once a month and antibody titers
monitored by enzyme-linked immunosorbent assay (ELISA). At
the end of the studies, mice were tested for functional effects in the
water maze. Brains and peripheral tissues were removed and
divided sagittally.
For studies of antibody trafficking into the CNS the mouse
monoclonal antibody 9E4 was concentrated with a 10-kDa cutoff
concentrator centrifuge tube (Millipore, Temecula, CA) and linked
to the Fluorescein isothiocyanate (FITC) molecule utilizing a
FluoroTag FITC conjugation kit (Sigma-Aldrich, St. Louis, MO)
according to the manufacturer’s instructions. For this experiment
non-tg (total n = 18) and a-syn tg mice (total n = 18) (6 m/o) were
injected intravenously (IV) with the 9E4-FITC or a non-immune
control FITC tagged IgG1 at a concentration of 1 mg/kg. Mice
were sacrificed 3, 14 and 30 days after injection (n = 3 per group).
CSF from these mice was used to immunolabel cortical sections
from antibody-naive animals.
As an additional control to monitor the passage of FITC-labeled
antibodies across the blood-brain barrier, mice were injected with
FITC tagged b-syn. The For this experiment non-tg (total n = 8)
and a-syn tg mice (total n = 8) (6 m/o) were injected intravenously
(IV) with the FITC-labeled b-syn or a non-immune control FITC
tagged IgG1 at a concentration of 1 mg/kg. Mice were sacrified at
14 days post-injection. CSF from these mice was also used to
immunolabel slides from FITC tagged b-syn niave non-tg and asyn tg mice.
Upon sacrifice, the right hemibrain was post-fixed in phosphatebuffered 4% PFA (pH 7.4) at 4uC for 48 hours for neuropathological analysis, while the left hemibrain was snap-frozen and
stored at 270uC for subsequent protein analysis. All experiments
described were approved by the animal subjects committee at the
University of California at San Diego (UCSD) and were
performed according to NIH recommendations for animal use.
UCSD is an Institutional Animal Care and Use Committee
accredited institution and the UCSD Animal Subjects Committee
PLoS ONE | www.plosone.org

Behavioral testing
Water maze. In patients with LBD, a-syn accumulates not
only in subcortical nuclei but also in the temporal cortex and
limbic system and accounts for cognitive deficits in these patients
[31]. Similarly, in our PDGF-a-syn tg mice, protein accumulation
occurs in the temporal cortex and hippocampus [28]. In this
context and as previously described [29], in order to evaluate the
functional effects of passive immunization treatment in mice,
groups of non-tg and a-syn tg animals were tested in the water
maze. For this purpose, a pool (diameter 180 cm) was filled with
opaque water (24uC) and mice were first trained to locate a visible
platform (days 1–3) and then a submerged hidden platform (days
4–7) in three daily trials 2–3 min apart. Mice that failed to find the
hidden platform within 90 seconds were placed on it for 30
seconds. The same platform location was used for all sessions and
all mice. The starting point at which each mouse was placed into
the water was changed randomly between two alternative entry
points located at a similar distance from the platform. In addition,
on the final day of testing the platform was removed and the time
spent by mice in the correct quadrant was measured (Probe test).
The duration of the probe test was 40 secs. Time to reach the
platform (escape latency) was recorded with a Noldus Instruments
EthoVision video tracking system (San Diego Instruments, San
Diego, CA) set to analyze two samples per second.
Pole Test. For the pole test, animals were placed head
upward on top of a vertical wooden pole 50 cm long and 1 cm in
diameter. When placed on the pole, animals orient themselves
downward and descend the length of the pole. Groups of mice
received training that consisted of five trials for each session. For
testing, animals received five trials and the time taken to descend
(T-total) was measured.
Rotarod. Mice were analyzed for 2 days in the Rotarod (San
Diego Instruments, San Diego, CA), as previously described
(Masliah et al., 2000). On the first day, mice were trained for five
trials: the first one at 10 rpm, the second at 20 rpm, and the third
to the fifth at 40 rpm. On the second day, mice were tested for
seven trials at 40 rpm each. Mice were placed individually on the
cylinder and the speed of rotation increased from 0 to 40 rpm over
a period of 240 s. The length of time mice remained on the rod
(fall latency) was recorded and used as a measure of motor
function.
2
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Table 1. Antibodies used for this study.

Antibody
name

Type of antibody

Epitope/
specificity

Antibody Isotype

Experimental
Use

27-1

Monoclonal

Control

IgG1

Control for Immunization

6H7

Monoclonal

NT 1-4

IgG1

Initial Characterization

8A5

Monoclonal

CT 125-140

IgG1

Initial
Characterization

9E4

Monoclonal

CT 118-126

IgG1

Passive Immunization

FL-a-syn

Polyclonal

FL

Affinity purified

ICC and IB

CC-a-syn

Polyclonal

CT 122-123

Affinity purified

ICC and IB

CT = C-terminus; FL = full length; CC = Calpain-cleaved; ICC = immunocytochemistry; IB = Immunoblot.
doi:10.1371/journal.pone.0019338.t001

NT-a-syn (9E4, 6H7 and 8A5, ELAN Pharmaceuticals). Analysis
of a-syn accumulation for the immunotherapy experiment was
performed in serially-sectioned, free-floating, blind-coded vibratome sections by incubating the sections overnight at 4uC with a
polyclonal antibody against total a-syn (1:500, affinity purified
rabbit polyclonal, Millipore) [27] and with an antibody against
the calpain-cleaved CT-a-syn [32], followed by secondary
antibodies tagged with FITC or biotinylated goat anti-rabbit
IgG1 (1:100, Vector Laboratories, Inc., Burlingame, CA), Avidin
D-HRP (1:200, ABC Elite, Vector) and detection with the
Tyramide Signal AmplificationTM-Direct (Red) system (1:100,
NEN Life Sciences, Boston, MA). In order to determine the
effects of immunotherapy on levels of total tau and PHF-tau
blotted samples from treated a-syn tg were probed with
antibodies against total tau (1:500, Dako, Carpinteria, CA) and
PHF-tau (1:500, UC Davis/NIH Neuro-Monoclonal Antibody
Facility, Davis, CA). Antibodies against Zo-1 (1:500, Millipore,
Temecula, CA), Iba-1 (1:1000, Wako, Richmond, VA) and
GFAP (1:1000, Millipore, Temecula, CA) were used to examine
the effects of passive immunization with 9E4 on vasculature or
glial cell activation respectively. All sections were processed
simultaneously under the same conditions and experiments were
performed in triplicate in order to assess the reproducibility of
results.
Stereological analysis and quantification of neocortical and
hippocampal intra-neuronal FL-asyn and CC-asyn immunoreactivity was conducted by the disector method using the StereoInvestigator System (MBF Bioscience, Williston, VT) and the
results were averaged and expressed as cell counts per 0.1 mm3.
Neocortical and hippocampal FL-asyn and CC-asyn immunoreactive neuropil was assessed in digital images analyzed with the
Image Quant software by selecting and area to exclude cell bodies,
setting the threshold levels and expressing the data as pixel
intensity (arbitary units).

ELISA analysis of brain and plasma antibody
concentrations
Antibody levels in the brain and plasma of immunized mice
were determined as previously described [17]. Briefly, using 96well microtiter plates coated with 0.4 mg per well of purified fulllength a-syn. Samples were incubated overnight followed by goat
anti-mouse IgG alkaline phosphatase-conjugated antibody
(1:7500, Promega, Madison, WI). The plate was read at
wavelengths of 450 nm and 550 nm. Results were plotted on a
semi-log graph with relative fluorescence units versus serum
dilution. Antibody titer was defined as the dilution at which there
was a 50% reduction from the maximal antibody binding.

Immunoblot analysis
Briefly, as previously described, brains were homogenized and
divided into cytosolic and membrane fractions [12,15]. For
immunoblot analysis, 20 mg of total protein per lane was loaded
into 4–12% Bis-Tris SDS-PAGE gels and blotted onto polyvinylidene fluoride (PVDF) membranes. For characterization of
the antibodies samples from untreated non-tg and a-syn tg mice
were incubated the with monoclonal antibodies against CT and NTerminal (NT) a-syn (9E4, 6H7 and 8A5, ELAN Pharmaceuticals). To determine the effects of the immunotherapy in levels of asyn blotted samples from treated a-syn tg were probed with
antibodies against calpain-cleaved a-syn (CC a-syn) which
recognizes a C-terminal fragment of a-syn [32], full length a-syn
(FL a-syn rabbit polyclonal (1:1000, Millipore, Temecula CA). For
the analysis of synaptic proteins, monoclonal antibodies against
Synapsin I (1:1000, Millipore, Temecula, CA) and PSD95 (UC
Davis/NIH Neuro-Monoclonal Antibody Facility, Davis, CA)
were used. In order to determine the effects of the immunotherapy
on levels of total tau and PHF-tau blotted samples from treated asyn tg were probed with antibodies against total tau (1:1000, Dako,
Carpinteria, CA) and PHF-tau (1:1000, UC Davis/NIH NeuroMonoclonal Antibody Facility, Davis, CA). Incubation with
primary antibodies was followed by species-appropriate incubation
with secondary antibodies tagged with horseradish peroxidase
(1:5000, Santa Cruz Biotechnology, Santa Cruz, CA), visualization
with enhanced chemiluminescence and analysis with a Versadoc
XL imaging apparatus (BioRad, Hercules, CA). Analysis of b-actin
(Sigma) levels was used as a loading control.

Double immunolabeling and fluorescence co-labeling
To determine the co-localization between a-syn and lysosomal
and autophagy markers double-labeling experiments were performed, as previously described [15]. For this purpose, vibratome
sections were immunolabeled with the rabbit polyclonal antibodies
against a-syn (Millipore, affinity purified polyclonal, 1:500) or CC
a-syn [27,32] and LC3 (Abcam) or cathepsin-D (Dako, 1:100).
The a-syn immunoreactive structures were detected with the
Tyramide Signal AmplificationTM-Direct (Red) system (1:100,
NEN Life Sciences, Boston, MA) while LC3 and cathepsin-D was
detected with FITC tagged antibodies (Vector, 1:75). Co-labeling
experiments were performed with antibodies against cathepsin-D

Immunocytochemical and neuropathological analyses
For characterization of the antibodies used for immunotherapy, vibratome sections from untreated non-tg and a-syn tg mice
were incubated the with monoclonal antibodies against CT and
PLoS ONE | www.plosone.org
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and LC3 detected with tyramide red in sections from mice that
received IV injections with the 9E4-FITC or IgG1-FITC. All
sections were processed simultaneously under the same conditions
and experiments were performed in triplicate in order to assess the
reproducibility of results. Sections were imaged with a Zeiss 63X
(N.A. 1.4) objective on an Axiovert 35 microscope (Zeiss) with an
attached MRC1024 LSCM (laser scanning confocal microscope)
system (BioRad) [27].

Statistical analysis
All experiments were done blind-coded and in triplicate. Values
in the figures are expressed as means 6 SEM. To determine the
statistical significance, values were compared using one-way
analysis of variance (ANOVA) with post hoc Dunnett’s test when
comparing to the IgG1 control. Additional comparisons were done
using Tukey-Kramer or Fisher post hoc tests. Repeated-measures
two-way ANOVA was used to analyze the water maze and
Rotarod data when comparing immunized mice to the non-tg or
IgG1 treated controls. The differences were considered to be
significant if p values were less than 0.05.

Electron microscopy and immunogold analysis
Briefly, vibratome sections were postfixed in 1% glutaraldehyde,
treated with osmium tetraoxide, embedded in epon araldite and
sectioned with the ultramicrotome (Leica, Germany). Grids were
analyzed with a Zeiss OM 10 electron microscope as previously
described [33]. For immunogold labeling, sections were mounted
in nickel grids, etched and incubated with biotin-tagged antibodies
against mouse IgG1 to detect the circulating antibodies utilized for
immunization or with antibodies against a-syn followed by
labeling with 10 nm Aurion ImmunoGold particles (1:50, Electron
Microscopy Sciences, Fort Washington, PA) with silver enhancement. A total of 125 cells were analyzed per condition. Cells were
randomly acquired from 3 grids, and electron micrographs were
obtained at a magnification of 25,000X.
For morphometric analysis of synapses from each section, a total
of 20 electron micrographs were obtained at a final magnification
of 12,000x. Electron micrographs were digitized and analyzed
with the Quantimet 570C (Leica, Deerfield, IL) to determine the
density of synapses per unit of volume.

Results
Initial characterization of novel monoclonal a-syn
antibodies and selection of antibody for passive
immunotherapy in a-syn tg mice
The PDGFb-a-syn tg mice were selected for the present study as
they display accumulation of a-syn in cortical and sub-cortical
regions and neuropathological and behavioral deficits consistent
with LBD [12,17,27,28,29,38]. In order to initially characterize
the specificity of the mouse monoclonal antibodies and to select
the one to be used for immunotherapy (Table 1) tissue sections and
brains homogenates from non-tg and a-syn tg mice were
examined by immunoblot and immunohistochemistry.
By immunoblot analysis (Figure S1A), the NT-a-syn antibody
(6H7) identified the a-syn monomer at 14 kDa in both the a-syn tg
mice and to a lesser degree in the non-tg mice. The antibodies
against CT- asyn (8A5, 9E4) antibodies specifically recognized the
a-syn monomer at 14 kDa in the a-syn tg mice (Figure S1A). No
immunoreactivity was observed with the IgG1 control (Figure S1A).
The FL a-syn antibody recognized monomeric a-syn in the a-syn tg
mice (Figure S1A). Consistent with a previous report [32] the
antibody against the calpain-cleaved (CC) a-syn, which recognizes a
C-terminally cleaved fragment of a-syn, produced a distinctive
pattern detecting a native band at 14 kDa. No cross-reactivity was
observed with these antibodies in the non-tg animals (Figure S1A).
Immunohistochemical analysis demonstrated that, compared to
the non-immune IgG1, (Figure S1B, C) antibodies against the NT
(6H7) (Figure S1D,E) and CT of a-syn (8A5) (Figure S1F, G), (9E4)
(Figure S1H,I) strongly immunolabeled the neuropil and the intraneuronal a-syn aggregates in the temporal cortex of the a-syn tg
mice. In the non-tg mice, there was a mild immunoreactivity with
the 8A5 antibody (Figure S1F), which was more prominent with the
6H7 antibody (Figure S1D). With the 9E4 antibody no immunoreactivity was detected in the non-tg mice (Figure S1H).
The patterns of immunostaining of the antibodies used for
immunotherapy were compared to a polyclonal antibody against
FL-a-syn (Figure S1J, K) and to the antibody against CC-a-syn,
(Figure S1L,M). In the a-syn tg mice, both antibodies immunolabeled
the intra-neuronal a-syn aggregates and the neuropil. The polyclonal
antibody against FL a-syn immunolabeled the neuropil in the non-tg
mice (Figure S1J), no immunoreactivity was detected with the
antibody against calpain-cleaved a-syn in these mice (Figure S1L).
Collectively these results demonstrate that the 9E4 antibody
directed against the CT of a-syn displayed the most specificity for
human a-syn, therefore this antibody was chosen for the
subsequent passive immunization study.

Neuronal cell cultures and treatments
The rat neuroblastoma cell line B103 was used for in vitro
experiments [34]. This model was selected because over
expression of a-syn in these cells interferes with neuronal
plasticity (reduced neurite outgrowth and adhesion) but does not
result in overt cell death [35,36]. This model mimics the early
pathogenic process of PD where cell death is preceded by
reduced neurite outgrowth and synaptic alterations. For all
experiments, cells were plated in complete media (Dulbecco’s
Modified Eagle Medium [Invitrogen, Carlsbad, CA] supplemented with 10% fetal bovine serum (Irvine Scientific, Santa
Ana, CA) and infected with LV expressing a-syn or controls at a
multiplicity of infection (MOI) of 40. After infection, cells were
incubated for 48 hr in a humidified 5% CO2 atmosphere at
37uC. All experiments were conducted in triplicate to ensure
reproducibility. To investigate the effects of the antibody
treatment on autophagy and a-syn, neuronal cells were grown
as described above and were then plated onto poly L-lysine
coated glass coverslips at a density of 56104 cells. Five hours
after plating, cells were infected with the LV-asyn LV-control
and incubated for 24 hours with 9E4 (3 mg/ml) or IgG1 control
in the presence or absence of inhibitors of the autophagy
pathway – 3-methyladenine (3-MA, 10 mM, Sigma) or inducers
– rapamycin (200 nM, Sigma) as previously described [15]. All
coverslips were also co-infected with an LV expressing LC3GFP at an MOI of 40. Cultures were then washed 2X with
serum-free DMEM and then fed either complete media or
serum-free media for 12 hours before fixation with 4% PFA.
Briefly as previously described [37], coverslips were treated with
Prolong Gold anti-fading reagent with DAPI (Invitrogen) and
imaged with the LSCM to determine the number of GFPpositive granular structures consistent with autophagolysosomes
using semiautomatic image analysis system and the ImageQuant
software. For each condition an average of 50 cells were
analyzed.
PLoS ONE | www.plosone.org

An antibody against CT-a-syn ameliorates motor and
learning deficits and synaptic pathology in a-syn tg mice
Following the initial screening and subsequent selection of the
9E4 antibody, a-syn tg and non-tg mice were passively immunized
4
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the visible period of training all 4 groups of mice performed
similarly. Following the cued platform session, the mice
underwent 4 days of testing during which the platform was
submerged and hidden from view (days 4–7). On the first day of
testing with the hidden platform all groups performed comparably, indicating that that were all able to swim and locate the
platform. Over the next 3 days of testing the performance of the
non-tg mice improved in terms of the distance of their swim path
and the time taken to locate the platform, During the submerged
platform segment of the test, the performance of the IgG1-treated
a-syn tg mice did not improve to the same extent as that observed
in the non-tg mice (Figure 2A, B, hidden platform). Upon
statistical analysis of performance with the submerged platform
(days 4–7) using repeated-measures two-way ANOVA a significant difference was observed between the IgG1-treated a-syn tg
mice and non-tg controls, with the IgG1-treated a-syn mice
taking a significantly longer path and longer time to locate the
hidden platform in comparison to their non-tg littermates
(Figure 2A, B, hidden platform). These results indicate that the
a-syn tg mice have a deficit in the learning and memory skills
associated with this task.
Analysis using repeated-measures two-way ANOVA demonstrated that mice immunized with the 9E4 antibody took a
significantly shorter path and time to locate the hidden platform in
comparison to IgG1-treated a-syn tg mice (Figure 2A, B, hidden
platform), indicating that passive immunization with this antibodies was able to ameliorate the memory and learning deficit
observed in the IgG1-treated a-syn tg mice. The time taken by the
9E4 immunized a-syn tg mice to find the submerged platform did
not differ significantly from that of the non-tg mice as determined
by repeated-measures two-way ANOVA. In the non-tg mice
immunization with the 9E4 antibody or the IgG1 control had no
deleterious effect upon their performance during the cued or
hidden portions of the water maze test (Figure 2A, B).
Following the final day of testing with the submerged platform
the mice underwent a Probe test. During this test the platform was
removed completely and the time spent by the mice in the correct
quadrant (that corresponding to the previous location of the
platform) was measured. A longer time spent in the correct

with either 9E4 or the control IgG1. Antibody titers in the
passively immunized a-syn tg and non-tg mice were analyzed by
ELISA. On average titer levels were comparable between passively
immunized a-syn tg and non-tg mice, though a greater variability
was observed within the a-syn tg group (Figure 1A).
The effects of passive immunization on motor behavior in the asyn tg mice was assessed using the rotarod and pole test. Results
from the pole test demonstrated a motor impairment in the IgG1treated a-syn tg mice compared to IgG1-treated non-tg mice,
evidenced by the significantly longer time taken by the a-syn tg
mice to traverse the pole as determined by one-way ANOVA
(Figure 1B). Immunization with the 9E4 antibody significantly
reduced the time taken by the a-syn tg mice to traverse the pole
when compared to IgG1-treated a-syn tg mice (Figure 1B). The
time taken to traverse the pole by the a-syn tg mice immunized
with the 9E4 antibody did not significantly different from the time
taken by the non-tg mice, as determined by one-way ANOVA
(Figure 1B).
Statistical analysis of the Rotarod results using repeatedmeasures two-way ANOVA demonstrated that IgG1-treated asyn tg mice spent significantly less time on the rotating rod in
comparison to IgG1-treated non-tg mice, suggesting that the a-syn
tg mice have deficits in motor coordination (Figure 1C). In
contrast, a-syn tg mice immunized with the 9E4 antibody spent a
significantly longer time on the rod when compared to IgG1treated a-syn tg mice, as determined by repeated-measures twoway ANOVA (Figure 1C). The time spent on the rod by a-syn tg
mice immunized with the 9E4 antibody did not differ from that of
the non-tg controls.
In order to evaluate the effects of passive immunization with
the CT a-syn antibody on memory and learning, following the 6month immunization period, mice were tested in the water maze.
During the initial training part of the test when the platform was
visible (days 1-3), all groups performed at comparable levels,
though a greater variability was observed in the IgG1-treated asyn tg mice (Figure 2A, B, cued platform), as determined by
repeated measures two-way ANOVA. At day 2 of the visible
platform 9E4-treated a-syn tg appear to reach the platform at a
faster rate compared to the other 3 group. However at the end of

Figure 1. Plasma antibody titers and effects of passive immunization on motor behavior in passively immunized a-syn tg mice. (A)
Antibody titers determined by ELISA in non-tg or a-syn tg mice immunized with the C-terminal antibody (9E4) or IgG1 controls. Horizontal lines
represent the mean of the data, whilst the points represent the spread of the individuals in each group. To examine the effects of immunization with
the 9E4 antibody on motor behavior in the a-syn tg, mice were tested in the rotarod and pole tests. (B) Pole test performance (time taken to traverse
pole) by non-tg mice or a-syn tg mice immunized with IgG1 or 9E4. N = 20 mice per group; 12 month old. Error bars represent mean 6 SEM. (C)
Rotarod performance (time spent on rotating rod) by non-tg mice or a-syn tg mice immunized with IgG1 or 9E4. Error bars represent mean 6 SEM.
When analyzing rotarod results (*) indicates p,0.05, when comparing a-syn tg immunized with IgG1 to non-tg group by repeated-measures two-way
ANOVA and (#) indicates p,0.05, when comparing a-syn tg mice immunized with 9E4 to IgG1 immunized a-syn tg mice using repeated-measures
two-way ANOVA. When analyzing pole test results (*) indicates p,0.05, when comparing a-syn tg immunized with IgG1 to non-tg group by one-way
ANOVA with post hoc Dunnett’s and (#) indicates p,0.05, when comparing a-syn tg immunized with 9E4 to IgG1 immunized a-syn tg mice by oneway ANOVA with post hoc Dunnett’s.
doi:10.1371/journal.pone.0019338.g001

PLoS ONE | www.plosone.org

5

April 2011 | Volume 6 | Issue 4 | e19338

Passive Immunization in LBD Model

Figure 2. Effects of passive immunization on behavioral performance in the water maze in passively immunized a-syn tg mice. (A)
Performance in the water maze (distance taken to locate platform) during training with the cued platform (days 1–3) and with the platform
submerged (days 4–7) in non-tg mice or a-syn tg mice immunized with IgG1 or 9E4. (B) Performance in the water maze (time to locate the platform)
during training with the cued platform (days 1–3) and with the platform submerged (days 4–7) in non-tg mice or a-syn tg mice immunized with IgG1
or 9E4. (C) Probe test performance (time spent in correct quadrant) (day 8) in non-tg mice or a-syn tg, mice immunized with IgG1 or 9E4. N = 20 mice
per group; 12 month old. Error bars represent mean 6 SEM. (D) Representative images of the swim paths of animals from each group when the
platform was visible (Day 3, trial 4, red box indicates the location of the platform), hidden (Day 7, trial 4, red box indicates the location of the platform
which is now submerged below the opaque surface) or absent (Day 8, Probe Test). When analyzing the water maze results (*) indicates p,0.05, when
comparing a-syn tg immunized with IgG1 to non-tg IgG1 group by repeated-measures two-way ANOVA and (#) indicates p,0.05, when comparing
a-syn tg immunized with 9E4 to IgG1 immunized a-syn tg mice by repeated-measures two-way ANOVA. When analyzing probe test results (*)
indicates p,0.05, when comparing a-syn tg immunized with IgG1 to non-tg IgG1 group by one-way ANOVA with post hoc Dunnett’s and (#)
indicates p,0.05, when comparing a-syn tg immunized with 9E4 to IgG1 immunized a-syn tg mice by one-way ANOVA with post hoc Dunnett’s.
doi:10.1371/journal.pone.0019338.g002

quadrant is indicative of a learning effect wherein the mice
remember the previous location of the platform and spend an
increased period of time looking for it, whilst a shorter time in this
quadrant indicates a memory deficit. Statistical analysis using oneway ANOVA demonstrated a significant decrease in the amount
of time spent in the correct quadrant by IgG1-treated a-syn tg
mice in comparison to non-tg control mice (Figure 2C) suggestive
of a memory deficit in these mice. In contrast, a-syn tg mice
immunized with the 9E4 antibody spent longer in the target area
when compared to IgG1-treated a-syn tg mice, as determined by
one-way ANOVA (Figure 2C). The time spent in the correct
quadrant by a-syn tg mice immunized with the 9E4 antibody did
not differ from that of the non-tg controls. These results suggest
that immunization with the 9E4 antibody was able to ameliorate
the memory deficits observed in the IgG1-treated a-syn tg mice.
No significant effects were observed in the probe test in non-tg
mice treated with the 9E4 antibody or the IgG1 control
(Figure 2C).
PLoS ONE | www.plosone.org

Representative images of the swim paths of mice from the
different groups are shown in Figure 2D for day 3, trial 4 (platform
visible, red box indicates location of platform) and day 7, trial 4
(platform hidden, red box indicates location of platform which
now submerged in the opaque water). When the platform was
visible all mice appeared to take a comparable path length to the
platform (Figure 2A D- Day 3, trial 4, Platform visible). When the
platform was submerged, IgG1-treated a-syn tg mice took a
significantly longer path and a more convoluted path to find the
platform (Figure 2A, D - Day 7, trial 4, Platform hidden). In
contrast, 9E4-immunized a-syn tg mice were able to locate the
hidden platform with a time comparable to that observed in the
IgG1-treated non-tg controls and with a much more direct path
than that observed with IgG1-treated a-syn tg mice (Figure 2A, D
- Day 7, trial 4, Platform hidden). In the probe test portion of the
water maze IgG1-treated a-syn tg mice did not spend a significant
amount of time in the correct quadrant (Figure 2C, D - Day 8,
Probe Test). In contrast, the a-syn tg mice that had been
6

April 2011 | Volume 6 | Issue 4 | e19338

Passive Immunization in LBD Model

demonstrated significantly reduced levels in the IgG1 treated asyn mice in comparison to non-tg control mice (Figure 3G, I).
Immunization with the CT-a-syn antibody 9E4 significantly
increased synapsin levels in the immunized a-syn tg mice in
comparison to the IgG1-treated a-syn tg mice (Figure 3G, I), as
determined by one-way ANOVA. Synapsin levels in the 9E4immunized a-syn tg mice did not differ significantly from those
observed in the non-tg mice (Figure 3G, I).
In the non-tg mice immunization with the 9E4 antibody or
IgG1 control had no deleterious effects upon PSDs, pre-synaptic
terminals or on synapsin I levels (Figure 3A, B, E-I).

immunized with 9E4 spent much longer in the correct quadrant,
comparable to the time observed in the IgG1-treated non-tg
controls (Figure 2C, D - Day 8, Probe Test).
Since improvements in behavioral performance may be related
to enhanced synaptic connectivity, synaptic structure was analyzed
by electron microscopy. Ultrastructural analysis (Figure 3) showed
that, compared to non-tg mice (Figure 3A), a-syn tg mice treated
with IgG1 displayed a significant reduction in the number of
postsynaptic densities (PSDs) and presynaptic terminal diameter
(Figure 3C, E, F), as determined by one-way ANOVA. In contrast,
immunization with the 9E4 antibody significantly increased the
number of PSDs (Figure 3D, E) and the diameter of pre-synaptic
terminals in the immunized a-syn mice (Figure 3D, F) in
comparison to the IgG1-treated a-syn tg mice, as determined by
one-way ANOVA. PSD number and pre-synaptic terminal
diameter in the a-syn tg mice immunized with the 9E4 antibody
did not significantly differ from that in the non-tg mice (Figure 3A,
D, E, F).
Consistent with the ultrastructural examination, immunoblot
analysis (Figure 3G) demonstrated that levels of PSD95 were
significantly reduced in the IgG1 treated a-syn tg mice compared
to non-tg mice, as determined by one-way ANOVA (Figure 3G,
H). The mice immunized with the 9E4 antibody displayed
significantly higher levels of PSD95 when compared to IgG1treated a-syn tg mice, as determined by one-way ANOVA
(Figure 3G, H). PSD levels in mice immunized with the 9E4
antibody were not significantly different from those in non-tg mice,
as determined by one-way ANOVA (Figure 3G, H). Similarly,
immunoblot analysis of Synapsin I, a presynaptic marker,

Passive immunotherapy with a CT a-syn antibody
reduces the accumulation of calpain-cleaved a-syn
aggregates
To investigate whether the behavioral and synaptic improvements in the immunized a-syn tg mice were associated with
reduced accumulation of a-syn, immunochemical studies were
performed with antibodies against FL and CC a-syn. CC-a-syn
has been proposed to serve as a substrate for aggregation and
antibodies against this epitope have been shown to identify
abnormal a-syn aggregates that otherwise are not detected in
control human brain or in wild-type mice [32]. With the
polyclonal FL a-syn antibody there was no significant difference
in the intra-neuronal inclusions in the temporal cortex in 9E4treated a-syn tg mice in comparison to IgG1-treated a-syn tg mice
(Figure 4C, D, I), however there was a small but significant
reduction of a-syn immunoreactivity in the neocortical neuropil of
the 9E4 treated mice in comparison to IgG1-treated a-syn tg mice

Figure 3. Analysis of the effects of passive immunization on synaptic structure and markers in a-syn tg animals. The effect of
immunization with the 9E4 antibody on synaptic markers was evaluated in the temporal cortex of non-tg and a-syn tg mice by electron microscopy
and immunoblot analysis. Representative electron micrographs are from the temporal cortex layers 5–6 obtained at 15,000 X. (A) non-tg mice
immunized with IgG1 control. (B) non-tg mice immunized with 9E4. (C) a-syn tg mice immunized with the IgG control. (D) a-syn tg mice immunized
with the 9E4 antibody. (E, F) Image analysis of the numbers of post-synaptic densities (PSD) and mean presynaptic terminal diameters respectively.
(G) Representative immunoblot for PSD95, a postsynaptic marker and Synapsin I, a presynaptic marker, in non-tg mice or a-syn tg mice immunized
with the IgG control or the 9E4 antibody. (H, I) Analysis of the levels of PSD95 and Synapsin I immunoreactive bands respectively. N = 20 mice per
group; 12 month old. Error bars represent mean 6 SEM. (*) indicates p,0.05, when comparing IgG1-immunized a-syn tg mice to IgG1-immunized
non-tg mice and (#) indicates p,0.05 when comparing a-syn tg mice immunized with 9E4 to IgG1 immunized a-syn tg mice using one-way ANOVA
with post hoc Dunnett’s.
doi:10.1371/journal.pone.0019338.g003
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Figure 4. Comparative immunohistochemical analysis with antibodies against full length or calpain-cleaved a-syn in passively
immunized a-syn tg mice. To examine the effects of immunization on a-syn accumulation, immunohistochemical analysis using antibodies against
FL-a-syn (layers 5–6) and CC-a-syn was conducted. Panels illustrate laser scanning confocal images of the temporal cortex and hippocampus (CA3)
immunolabeled with antibodies against FL and CC a-syn immunoreactivity. (A, C) Temporal cortex of IgG1-immunized non-tg and a-syn tg mouse
immunolabeled with an antibody against FL-a-syn, respectively. (B, D) Temporal cortex of 9E4-immunized non-tg and a-syn tg mouse
immunolabeled with an antibody against FL-a-syn, respectively. (E, G) Hippocampus of IgG1-immunized non-tg and a-syn tg mouse immunolabeled
with an antibody against FL-a-syn, respectively. (F, H) Hippocampus of 9E4-immunized non-tg and a-syn tg mouse immunolabeled with an antibody
against FL-a-syn, respectively. (I) Image analysis of the numbers of neocortical a-syn immunoreactivity neurons with the FL a-syn antibody. (J)
Analysis of the levels of a-syn immunoreactivity in the neuropil in the neocortex in sections labeled with the FL a-syn antibody. (K) Image analysis of
the numbers of hippocampal a-syn immunoreactivity neurons with the FL a-syn antibody. (L) Analysis of the levels of a-syn immunoreactivity in the
neuropil in the hippocampus in sections labeled with the FL a-syn antibody. (M, O) Temporal cortex of IgG1-immunized non-tg and a-syn tg mouse
immunolabeled with an antibody against CC a-syn, respectively. (N, P) Temporal cortex of 9E4-immunized non-tg and a-syn tg mouse
immunolabeled with an antibody against CC a-syn, respectively. (Q, S) Hippocampus of IgG1-immunized non-tg and a-syn tg mouse immunolabeled
with an antibody against CC a-syn, respectively. (R, T) Hippocampus of 9E4-immunized non-tg and a-syn tg mouse immunolabeled with an antibody
against CC a-syn, respectively. (U) Image analysis of the numbers of neocortical a-syn immunoreactivity neurons with the CC a-syn antibody. (V)
Analysis of the levels of a-syn immunoreactivity in the neuropil in the neocortex in sections labeled with the CC a-syn antibody. (W) Image analysis of
the numbers of hippocampal a-syn immunoreactivity neurons with the CC a-syn antibody. (X) Analysis of the levels of a-syn immunoreactivity in the
neuropil in the hippocampus in sections labeled with the CC a-syn antibody. Scale bar = 30 mM. N = 20 mice per group; 12 month old. Error bars
represent mean 6 SEM. (*) indicates p,0.05, when comparing IgG1-immunized a-syn tg mice to IgG1-imunized non-tg mice by one-way ANOVA
with post hoc Dunnett’s. (#) Indicates p,0.05, when comparing a-syn tg mice immunized the 9E4 a-syn antibody to IgG1-treated a-syn tg mice by
one-way ANOVA with post hoc Dunnett’s.
doi:10.1371/journal.pone.0019338.g004

tg mice treated with the IgG1 control. Similarly, neocortical a-syn
immunoreactive neuropil in a-syn tg mice immunized with the
9E4 antibody displayed a 57% reduction in the accumulation of
CC a-syn when compared to a-syn tg mice treated with the IgG1
control. In the hippocampus of a-syn tg mice immunized with the
9E4 antibody intra-neuronal a-syn immunoreactivity, as detected
by the CC-a-syn antibody was reduced 90% when compared to asyn tg mice treated with the IgG1 control.
Hippocampal a-syn immunoreactive neuropil in a-syn tg mice
immunized with the 9E4 antibody displayed a 33% reduction in
the accumulation of CC a-syn when compared to a-syn tg mice
treated with the IgG1 control.
In the IgG1- or 9E4-treated non-tg mice the FL and CC-a-syn
antibodies detected minimal levels of a-syn in neocortical or
hippocampal neurons (Figure 4A, B, I, E, F, K, M, N, U, V, Q, R,

(Figure 4C, D, J). In the hippocampus there were no significant
differences in FL a-syn immunoreactivity in intra-neuronal inclusions
or neuropil between the 9E4-treated a-syn tg mice and IgG1-treated
a-syn tg mice control groups (Figure 4G, H, K, L)
In contrast, immunohistochemical analysis with the antibody
against CC a-syn showed a significant reduction in the levels of
immunoreactivity in the both the numbers of immunolabeled
intra-neuronal aggregates and the neuropil in the temporal cortex
and hippocampus in the a-syn tg mice treated with the 9E4
antibody when compared to a-syn tg mice treated with the IgG1
control (temporal cortex, Figure 4O, P, U, V), hippocampus,
Figure 4S, T, W, X).
In the temporal cortex of a-syn tg mice immunized with the 9E4
antibody intra-neuronal a-syn immunoreactivity, as detected by
the CC-a-syn antibody was reduced 43% when compared to a-syn
PLoS ONE | www.plosone.org
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W, X). However the FL a-syn antibody was able to detect low
levels of a-syn in the neuropil of these regions in the non-tg mice
(Figure 4A, J, E, L).
Consistent with immunohistochemical findings, immunoblot
analysis with the polyclonal antibody against FL a-syn (Figure 5A)
showed similar levels of a-syn monomer (Figure 5B) and oligomer
species (Figure 5C) in the soluble fraction of 9E4-treated a-syn tg mice
when compared IgG1-treated a-syn tg mice. Levels of a-syn
oligomers in the insoluble fraction were significantly reduced in the
a-syn tg mice immunized with the 9E4 antibody compared to IgG1treated a-syn tg mice (Figure 5D, F), whilst levels of a-syn monomers
were low and appeared unaffected by immunization (Figure 5D, E).
Immunoblot analysis with the antibody against CC a-syn in the
soluble fraction showed a significant decrease in a-syn monomers
and oligomers in 9E4-treated a-syn tg mice, in comparison to the
IgG1-treated a-syn tg mice (Figure 5G–I). In the insoluble fraction
the CC a-syn antibody showed a reduction of approximately 70%
in the levels of monomeric a-syn band (Figure 5J, K) and a 95%
reduction in the levels of the bands corresponding to oligomers in
the insoluble fraction in the 9E4-treated a-syn tg mice group in
comparison to the IgG1-treated a-syn tg mice (Figure 5J, L). In the
non-tg mice immunization with the 9E4 antibody had no effect
upon levels of FL- or CC-a-syn (Figure 5).
Given the recent results from genome-wide association studies
suggesting that tau may play an important role in a-synucleinopathies
such as PD [39,40] we examined the effect of passive immunization
with 9E4 on levels of tau and PHF-tau in the a-syn tg mice (Figure
S2). Immunohistochemical analysis of the frontal cortex using an
antibody against tau did not show significantly different levels of total
tau between IgG1-treated a-syn tg and non-tg mice (Figure S2A, C,
E), in contrast, IgG1-treated a-syn tg mice had significantly higher
levels of PHF-tau, a four-fold increase in comparison to IgG1-treated
non-tg mice (Figure S2F, H, J). 9E4 immunization did not alter levels
of total tau (Figure S2B, D, E,) or PHF-tau (Figure S2G, I, J) in either
group. Immunoblot analysis of total and PHF-tau levels was
consistent with the immunohistochemical results and demonstrated
no effect of 9E4 immunization on levels of total or PHF-tau in a-syn
tg or non-tg mice (Figure S2K–M).
As passive immunization has been suggested to perturb
vasculature we performed immunohistochemical analysis with
the endothelial cell marker Zo-1 to examine the effects of
immunization with the 9E4 antibody. In IgG1-treated non-tg
and a-syn tg mice Zo-1 immunoreactivity was observed in the
neuropil in association with the microvasculature and immunization with 9E4 had no effect upon Zo-1 immunoreactivity in either
group (Figure S3A–E).
Immunohistochemical analysis of glial cell reactivity surrounding the vasculature was performed using markers against
microglial and astroglial activation (Iba-1 and GFAP, respectively).
IgG1- and 9E4-treated non-tg mice showed similar patterns of
Iba-1 immunoreactivity in the neuropil around the blood vessels
(Figure S3F, G, J). There was a moderate increase in Iba-1
immunoreactive microglial cells in the IgG1-treated a-syn tg mice
in comparison to the IgG1-treated non-tg mice (Figure S3F, H, J)
and no difference in Iba-1 immunoreactivity was observed the
IgG1- or 9E4-treated a-syn tg mice (Figure S3H–J).
In the non-tg mice scattered GFAP immunoreactive astroglial
cells were observed in the neuropil surrounding blood vessels
(Figure S3K), no differences in the levels of GFAP were observed
between IgG1- and 9E4-treated non-tg mice (Figure S3K, L, O).
In contrast, the IgG1-treated a-syn tg mice had a robust increase
in GFAP immunoreactivity in comparison to the IgG1-treated
non-tg mice (Figure S3K, M, O) and passive immunization with
9E4 was able to reduce GFAP immunoreactivity in the a-syn tg
PLoS ONE | www.plosone.org

mice (Figure S3M–O) resulting in a normalization of astroglial
cells around the blood vessels in these mice.
Collectively the results thus far demonstrate that the 9E4
antibody is specific for human a-syn, significantly ameliorates the
motor and memory/learning deficits examined in the a-syn tg
mice and is effective at reducing the accumulation of a-syn in asyn tg mice. Additionally these beneficial effects of 9E4 did not
perturb the microvasculature.

A monoclonal antibody against CT-a-syn traffics into the
CNS and localizes to lysosomes
In order to evaluate the trafficking of 9E4 into the CNS, 9E4 and a
control IgG1 were labeled with FITC and injected intravenously into
non-tg and a-syn tg. At 3 days post injection low levels of the 9E4
antibody were detected in the brain, while high levels were detected
in plasma (Figure 6A). At 14 and 30 days post injection higher levels
were detected in the brain with decreasing levels in the plasma as
detected by ELISA (Figure 6A). By immunohistochemistry the 9E4FITC antibody was detected in association with neurons in the brains
of a-syn tg mice at 30 days post injection (Figure 6B). The 9E4-FITC
antibody was detected in association with granular structures in
neurons distributed in the deeper layers of the temporal cortex and
the CA1-2 region of the hippocampus only in the brains of a-syn tg
mice (Figure 6C, D). Control experiments with a non-immune IgG1FITC show only background labeling in a-syn tg mice (Figure 6E). In
non-tg mice only low levels of 9E4-FITC labeling were detected in
blood vessels (Figure 6F).
To further confirm that the 9E4-FITC antibody crossed the
blood-brain barrier (BBB) and circulated in the CNS, CSF from
mice immunized with the IgG-FITC or 9E4-FITC antibodies was
used to label sections from antibody-naive a-syn tg mice. These
studies demonstrated that the CSF from mice immunized with the
9E4-FITC antibody immunolabeled synapses and neurons in the
antibody-naive a-syn tg (Figure 6G), in contrast no labeling was
observed with the CSF of mice treated with non-immune IgG1FITC (Figure 6H).
As an additional control to assess the passage of a FITC-labeled
protein into the brain, a-syn tg and non-tg mice were injected with
FITC-labeled b-syn (Figure S4). No signal in the FITC channel
was observed upon direct visualization of cortical sections from
these mice (Figure S4A, B), as would be expected given that b-syn
is a predominantly cytoplasmic protein and, unlike a-syn, has not
been reported at the plasma membrane. However when CSF from
mice injected with the FITC-labeled b-syn was used to
immunolabel sections from naive a-syn tg and non-tg mice (those
that had not been injected with the FITC-b-syn), a clear
immunoreactivity was observed in the cortex of both non-tg and
a-syn tg mice (Figure S4C and D).
To determine whether a-syn co-localizes to the structures
decorated by 9E4-FITC, co-labeling experiments were performed.
Laser scanning confocal microscopy in sections from a-syn tg mice
showed that the granular structures within the neurons labeled
with 9E4-FITC antibody co-localized with a-syn immunoreactivity (Figure 7A–C). These, intra-neuronal structures labeled by the
9E4-FITC displayed LC3 (Figure 7D–F) and cathepsin-D
immunoreactivity (Figure 7G–I). To corroborate the localization
of the 9E4 antibody to the lysosomes, immuno-electron microscopic analysis was performed with a gold-tagged anti-mouse
antibody. Ultrastructural analysis confirmed the presence of
immunogold particles in the lysosomes and autophagosomes in
the brains of a-syn tg mice treated with 9E4 (Figure 7J, K). In
contrast, no specific labeling of lysosomes or autophagosomes
was detected in the brains of a-syn tg mice treated with the
9
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Figure 5. Immunoblot analysis with antibodies against full length and calpain-cleaved a-syn in passively immunized a-syn tg mice.
To evaluate the effects of immunization on a-syn accumulation, immunoblot analysis using antibodies against FL-asyn and CC-a-syn was conducted.
(A) Representative immunoblot with anti-FL a-syn of the soluble fraction from non-tg and a-syn tg mice immunized with IgG1 control or 9E4. (B, C)
Analysis of the levels of the a-syn immunoreactive bands corresponding to the monomer and oligomers respectively, as detected by the FL a-syn
antibody in the soluble fraction. (D) Representative immunoblot with anti-FL a-syn of the insoluble fraction from non-tg and a-syn tg mice
immunized with IgG1 control or 9E4. (E, F) Analysis of a-syn monomer or oligomer levels respectively, detected by the FL a-syn antibody in the
insoluble fraction. (G) Representative immunoblot with anti-CC a-syn of the soluble fraction from non-tg and a-syn tg mice immunized with IgG1
control or 9E4. (H, I) Analysis of a-syn monomer or oligomer levels respectively detected by the CC a-syn antibody in the soluble fraction. (J)
Representative immunoblot with anti-CC a-syn of the insoluble fraction from non-tg and a-syn tg mice immunized with IgG1 control or 9E4. (K, L)
Analysis of a-syn monomer or oligomer levels respectively, detected by the CC a-syn antibody in the insoluble fraction. N = 20 mice per group; 12
month old. Error bars represent mean 6 SEM. (*) indicates p,0.05, when comparing IgG1-immiunized a-syn tg mice with IgG1-immunized non-tg
mice using one-way ANOVA with post hoc Dunnett’s. (#) indicates p,0.05, when comparing a-syn tg mice immunized with 9E4 with IgG1
immunized a-syn tg mice using one-way ANOVA with post hoc Dunnett’s.
doi:10.1371/journal.pone.0019338.g005

non-immune IgG1 (Figure 7L, M) or in the neurons non-tg mice
treated with 9E4 (Figure 7N, O).
Taken together, these studies suggest that the 9E4 antibody can
cross the BBB and bind a-syn and it is possible that the resulting
antibody-antigen complex may then be endocytosed and transferred into the lysosomal compartment for degradation.
PLoS ONE | www.plosone.org

Passive immunotherapy with a monoclonal antibody
against CT-a-syn activates the autophagy pathway
Since passive immunotherapy in this system appears to promote
clearance of a-syn via a lysosomal pathway we investigated
whether treatment with the 9E4 antibody activated the autophagy
pathway in the a-syn tg immunized mice. Compared to control
10
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Figure 6. Trafficking of the FITC-tagged a-syn 9E4 antibody in tg mice. To investigate the distribution of the 9E4 antibody after passive
immunization, the FITC tagged antibody was injected intravenously (IV) and analyzed by ELISA and confocal microscopy. (A) Antibody titers in the
plasma and brain at 3, 14 and 30 days post-injection in mice immunized with the 9E4 antibody, determined by ELISA. (B) Image analysis of 9E4-FITC
positive neurons in the a-syn tg mice at 3, 14 and 30 days post-injection. (C, D) Representative laser scanning confocal images of the signal in the FITC
channel in the temporal cortex of a-syn tg mouse 30 days following intravenous IV injection with the FITC-tagged 9E4 antibody. Arrows highlight
labeled intra-neuronal granular-like structures. (E) No signal is detected in the FITC channel in a-syn tg mouse 30 days following IV injection with the
FITC-tagged IgG1 control antibody. (F) No signal in the FITC channel in non-tg mouse 30 days following IV injection with the FITC-tagged 9E4
antibody. (G) Confocal image of a section from an antibody-naive a-syn tg mouse immunolabeled with cerebrospinal fluid (CSF) from a mouse
immunized with 9E4-FITC. (H) Confocal image of a section from non-tg mouse immunolabeled 9E4-FITC antibody. Scale bar (C, E–H) = 50 mM; (D)
= 10 mM. N = 20 per group, 12 months of age. Error bars represent mean 6 SEM.
doi:10.1371/journal.pone.0019338.g006

experiments where a-syn tg mice treated with IgG1 displayed
discrete LC3 and cathepsin-D immunoreactivity granules, in the
a-syn tg mice treated with the 9E4 antibody there was a
significant increase in the neuronal levels of LC3 (Figure 8A-C)
and cathepsin-D immunoreactivity (Figure 8D–F) This was
accompanied by a decrease in the levels of intra-neuronal and
synaptic CC a-syn accumulation and the compartmentalization
of a-syn to granular structures (Figure 8G-I). Double labeling
experiments confirmed that in the a-syn tg mice treated with the
9E4 antibody a-syn colocalized with the lysosomal (cathepsin-D)
(Figure 8J–L) and autophagy (LC3) (Figure 8M–O) markers.
Additional immunohistochemical was performed to confirm the
co-localization of a-syn with LC3 in the 9E4 treated a-syn tg
mice, which was absent in the IgG1 controls (Figure S5A–I).
Further electron microscopy demonstrated a significant increase
in the levels of gold-labeled a-syn particles in the phagosomes of
9E4 immunized a-syn tg mice in comparison to IgG1 controls
(Figure S5J–N). Consistent with the immunohistochemistry,
immunoblot analysis showed levels of LC3 breakdown and
Beclin-1 immunoreactivity were increased in a-syn tg mice
PLoS ONE | www.plosone.org

treated with the 9E4 antibody compared to the non-immune
IgG1 (Figure 9A, B). Other genes expressed during autophagy,
such as Atg 7 and Atg 10, remained stable with the 9E4 treatment
in the a-syn tg mice (Figure 9A, B).
To confirm that the 9E4 antibody promotes clearance of a-syn
aggregates via autophagy, in vitro experiments were performed in a
neuronal cell line (B103 rat neuroblastoma cells [34]) expressing
Lenti-virus (LV) a-syn and the reporter gene LC3-GFP. Under
basal conditions neuronal cells expressing a control LV and
treated with IgG1 only displayed discrete LC3-GFP granules
(Figure 10A). Neuronal cells overexpressing a-syn showed the
presence of enlarged LC3-GFP granules that co-localized with asyn (Figure 10B). Treatment of the neuronal cells infected with the
LV- a-syn with the 9E4 antibody resulted in an increase number
of normal appearing LC3-GFP granules with a considerable
decrease in the accumulation of a-syn in the cytoplasm
(Figure 10C). In these neuronal cells, granular a-syn deposits colocalized to LC3-GFP structures representing autophagosomes
(Figure 10C). The effects of the 9E4 antibody at reducing a-syn
and elevating LC3-GFP were enhanced by rapamycin (an inducer
11
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Figure 7. Co-localization of the FITC-tagged a-syn 9E4 antibody with lysosomal and autophagosomal markers. To analyze the subcellular distribution of the 9E4 antibody immunohistochemical and ultrastructural analysis was conducted in 9E4-FITC immunized a-syn tg mice. (A–
C) Representative confocal image of a brain section from an a-syn tg mouse immunized 9E4-FITC and co-labeled with an antibody against a-syn.
Arrows indicate co-localization of the 9E4-FITC signal with a-syn in neuronal granular-like structures. (D–F) Confocal image from an a-syn tg mouse
immunized 9E4-FITC and co-labeled with an antibody against LC3. Arrows indicate co-localization of the 9E4-FITC with LC3 in neuronal
autophagosome-like structures. (G–I) Confocal image from an a-syn tg mouse immunized 9E4-FITC and co-labeled with an antibody against
cathepsin D. Arrows indicate co-localization of the 9E4-FITC with cathepsin-D in neuronal lysosomal-like structuresLC3. (J, K) Representative electron
micrographs of sections from an a-syn tg mouse immunized with the 9E4 antibody and immunolabeld with gold-tagged anti-mouse antibody. (L, M)
Electron micrographs of sections from an a-syn tg mouse immunized with the control IgG1 antibody and immunolabeld with gold-tagged antimouse antibody. (N, O) Representative electron micrographs of sections from a non-tg mouse immunized with the 9E4 antibody and immunolabeld
with gold-tagged anti-mouse antibody. No reactivity is observed in lysosomes or autophagosomes. Scale bar (A–I) = 10 mM; (J–O) magnification
25,000x.
doi:10.1371/journal.pone.0019338.g007

interactions with the CT domain of a-syn [10,42]. Therefore it
is possible that antibody targeting of this region may reduce the
generation of this toxic species.
Calcium dependent calpain activation cleaves a-syn at the CT
between amino acids 121–123 [32]. The cleavage of a-syn at
either the NT or CT end of a-syn could be detected in the brains
of patients with PD and DLB using two site-directed calpaincleavage antibodies [32]. Calpain can cleave a-syn in vitro, leading
to its aggregation and adoption of a b-sheet conformation.
Therefore, immunization with antibodies against the CT of
a-syn might be protective either by blocking the CT cleavage of
a-syn, recognizing and promoting the clearance of CT fragments
and aggregates of a-syn or by blocking the interaction of CT
fragments with FL a-syn. In support of this possibility the present
study showed that passive immunotherapy reduced the accumulation and formation of CT fragments compared to FL a-syn. The
antibody against the calpain-cleaved a-syn utilized for this study
has been shown to recognize both the free a-syn fragments as well
as those complexed in oligomers [32]. These antibodies are
sensitive at recognizing sets of a-syn aggregates that appear

of autophagy) (Figure 10E, G and H) and were blocked by 3-MA
(an inhibitor of autophagy) (Figure 10F, I and J).
Taken together, these results support the possibility that passive
immunization with antibodies against the CT of a-syn promotes
clearance of a-syn aggregates via autophagy.

Discussion
The present study is the first to demonstrate that passive
immunization with an antibody directed at the CT of a-syn is able
to reduce memory/learning deficits and promote clearance of
cortical and hippocampal a-syn aggregates in tg mice expressing
human a-syn under the PDGFb promoter. This is consistent with
a previous study utilizing active immunization where epitope
mapping indicated that the best results in terms of reducing a-syn
was observed with antibodies that preferentially recognize the CT
of a-syn [17]. Though the reason for the enhanced activity of the
antibodies against the CT of a-syn is not completely understood,
recent studies have supported the possibility that the generation of
neurotoxic a-syn aggregates involves CT cleavage [41] and
PLoS ONE | www.plosone.org
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Figure 8. Immunocytochemical analysis of the effects of passive immunization with 9E4 in markers of lysosomes and autophagy in
a-syn tg mice. To examine the sub-cellular distribution of the 9E4 antibody immunohistochemical and ultrastructural analysis was conducted in 9E4
immunized a-syn tg mice. (A) LC3 immunoreactivity in a-syn tg mouse immunized with IgG1 antibody. (B) LC3 immunoreactivity in a-syn tg mouse
immunized with 9E4 antibody. (C) Analysis of LC3 immunoreactivity in a-syn tg mice immunized with IgG1 or 9E4 antibody. (D) Cathepsin-D
immunoreactivity in a-syn tg mouse immunized with IgG1 antibody. (E) Cathepsin-D immunoreactivity in a-syn tg mouse immunized with 9E4
antibody. (F) Analysis of cathepsin-D immunoreactivity in a-syn tg mice immunized with IgG1 or 9E4 antibody. (G) CC a-syn immunoreactivity in asyn tg mouse immunized with IgG1 antibody. (H) CC a-syn immunoreactivity in a-syn tg mouse immunized with 9E4 antibody. (I) Analysis of % area
of CC a-syn immunoreactive neuropil in a-syn tg mice immunized with IgG1 or 9E4 antibody. (J–L) Co-localization of a-syn and cathepsin-D
immunoreactivity in a-syn tg mouse immunized with 9E4 antibody. (M–O) Co-localization of a-syn and LC3 immunoreactivity in a-syn tg mouse
immunized with 9E4 antibody. Scale bar (A, B) = 30 mM (D, E, G and H) = 20 mM, (J–O) = 10 mM. (*) Indicates p,0.05, when comparing IgG1 to 9E4
group by unpaired Student’s t test. Error bars represent mean 6 SEM.
doi:10.1371/journal.pone.0019338.g008

pathological condition the aggregated a-syn tends to accumulate in
the membrane [21,47,48,49] and to be exposed to the extracellular compartment. Moreover, neurotoxic a-syn oligomers can be
secreted via exosomes into the extracellular space [50,51,52] and
can be detected in the CSF [26,53]. This suggests that the
antibodies might recognize a-syn aggregates lying in the cell
surface that in turn might be internalized and cleared via the
autophagy pathway. In support of this possibility, in the present
study we showed that systemically administered FITC-tagged
antibodies against a-syn traffic into the CNS and are internalized
by a-syn containing neurons and identified by double labeling and
immunogold in lysosomes and autophagosomes. Moreover, a-syn
was detected in LC3-positive granular structures further supporting a role for the autophagy-mediated clearance of a-syn in the
immunized animals. This is consistent with recent studies showing
that activating the autophagy pathway with pharmacological
[54,55] or gene therapy approaches promote elimination of a-syn
aggregates and ameliorates the deficits in tg mice [12,15].
Previous work by our group has shown that active immunization with recombinant a-syn ameliorates a-syn related synaptic
pathology in a tg mouse model of PD [17], however given the
common immunological problems that have often been associated
with active immunization we chose to pursue a passive
immunization protocol for this study. Our results indicate that
passive immunization is as effective as active for the sequestration
and removal of a-syn aggregates. It is interesting to note that both
the passive and active immunization approaches to a-syn

relevant to the disease process, given that such immunoreactivity is
not found in control cases or other neurodegenerative disorders
[32,43]. In the brains of patients with DLB as well as in the tg
models, a-syn aggregates containing CT-fragments not only
accumulate in the cell bodies but also in axons and nerve
terminals. In the tg animals, immunotherapy reduced the
accumulation of a-syn preferentially in the neuropil. This was
associated with improved behavioral performance in the water
maze and expression of the post-synaptic markers such as PSD95.
This is consistent with recent studies supporting the view that
neurotoxic a-syn accumulates preferentially in synapses and that asyn interferes with synaptic function [44,45]. Therefore promoting
the clearance of a-syn aggregates could be beneficial and result in
functional improvements.
Potential explanations for the preferential beneficial effects of
antibodies against the CT of a-syn include the possibility the CT
epitopes in a-syn might be more readily exposed facilitating
recognition by the antibody. For example, molecular modeling
and nuclear magnetic resonance studies suggest that while the NT
of a-syn interacts with the membrane [22], the CT tail is more
rigid [46], capable of penetrating the membrane and be freely
exposed to the external membrane surface where it can be
recognized by the antibodies [21,22]. Given that under physiological conditions a-syn is primarily a cytosolic protein it is
puzzling how the antibodies utilized for the passive immunization
strategies described in this study might recognize and trigger the
clearance of a-syn. In this regard it is worth noting that under

Figure 9. Immunoblot analysis of the effects of passive immunization with 9E4 in molecular components of the autophagy pathway
in a-syn tg mice. (A) Immunoblot analysis of mTor, Beclin 1, LC3, Atg 5, Atg 7, and Atg 10 protein immunoreactivity in a-syn tg mice that had been
immunized with either the IgG1 control or 9E4 antibody. (B) Analysis of mTor, Beclin 1, LC3, Atg 5, Atg 7, and Atg 10 protein levels in a-syn tg mice
that had been immunized with either the IgG1 control or 9E4 antibody. (*) Indicates p,0.05, when comparing IgG1 to 9E4 group by unpaired
Student’s t test. Error bars represent mean 6 SEM.
doi:10.1371/journal.pone.0019338.g009
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Figure 10. The effects of the 9E4 monoclonal antibody on promotion of a-syn clearance via autophagy in a neuronal cell model. (A)
Baseline co-localization of a-syn and LC3-GFP in neuronal cells infected with LV-control and treated with the IgG1 control antibody. (B) Baseline colocalization of a-syn and LC3-GFP in neuronal cells infected with LV-a-syn and treated with the IgG1 control antibody. (C) Co-localization of a-syn and
LC3-GFP in neuronal cells infected with LV-a-syn and treated with the 9E4 antibody. (D) Co-localization of a-syn and LC3-GFP in neuronal cells
infected with LV-control, treated with the IgG1 control antibody and rapamycin, an inducer of autophagy. (E) Co-localization of a-syn and LC3-GFP in
neuronal cells infected with LV-a-syn, treated with the 9E4 antibody and rapamycin, an inducer of autophagy. (F) Co-localization of a-syn and LC3GFP in neuronal cells infected with LV-a-syn, treated with the 9E4 antibody and 3MA, an inhibitor of autophagy. (G) Analysis of a-syn
immunoreactivity in neuronal cells infected with LV-a-syn, treated with the 9E4 antibody and rapamycin. (H) Analysis of LC3-GFP signal in neuronal
cells infected with LV-a-syn, treated with the 9E4 antibody and rapamycin. (I) Analysis of a-syn immunoreactivity in neuronal cells infected with LV-asyn, treated with the 9E4 antibody and 3MA. (J) Quantitative analysis of LC3-GFP signal in neuronal cells infected with LV-a-syn, treated with the 9E4
antibody and 3MA. Scale bar (A–F) = 10 mM (*) Indicates p,0.05 compared to LV-control infected and vehicle-treated cultures by one-way ANOVA
with post-hoc Dunnett’s test. (#) Indicates p,0.05 compared to LV-control infected and vehicle-treated cultures by one-way ANOVA with post-hoc
Tukey-Kramer test. Error bars represent mean 6 SEM.
doi:10.1371/journal.pone.0019338.g010

analysis was conducted to characterize the different a-syn
antibodies and to select the one that was subsequently used for
passive immunotherapy. Western blot analysis was performed with
soluble fraction from the temporal cortex. (A) Immunoblot analysis
in non-tg and a-syn tg mice with IgG1 control and the mouse
monoclonal antibodies against -a-syn- 6H7, 8A5, 9E4 and the
polyclonal antibodies against full-length (FL) a-syn and Calpain
cleaved (CC) a-syn. (B, C) Background levels of immunostaining
with the control IgG1 in non-tg and a-syn tg, respectively. (D, E)
Representative confocal images with the 6H7 antibody in non-tg
and a-syn tg, displaying immunostaining in the neuropil and
neurons in the temporal cortex respectively. (F, G) Confocal
images with the 8A5 antibody in non-tg and a-syn tg, displaying
immunostaining in the neuropil and neurons respectively. (H, I)
Confocal images with the 9E4 antibody in non-tg showing no
specific labeling and immunostaining in the neuropil and neurons
in a-syn tg. (J, K) FL a-syn immunoreactivity in non-tg and a-syn
tg, respectively. (L, M) CC a-syn immunoreactivity in non-tg and
a-syn tg, respectively). N = 3 per group, 6 months of age. Scale
bar (B-M) = 30mM.
(TIF)

eventually result in the recruitment of the autophagocytic pathway
indicating that key mechanisms may be involved in the
degradation of a-syn.
Passive immunization with antibodies against amyloid-beta (Ab
has been extensively investigated as a potential treatment modality
for AD [56,57,58,59]. These studies have been bolstered by the
fact that Ab is secreted and easily accessible to antibody
recognition. However a number of recent studies have shown
that similarly to a-syn, immunotherapy can reduce the accumulation of other membrane bound and intracellular protein
aggregates such as tau [60,61], PrP [62] and huntingtin [63].
In conclusion, we show that a monoclonal antibody against CT
a-syn traffics into the CNS, recognizes a-syn aggregates in affected
neurons and ameliorates behavioral and neuropathological
alterations in a-syn tg mice. Taken together, the results from this
study support the view that passive immunization with antibodies
against the CT of a-syn might have therapeutic potential in the
treatment of PD and DLB.

Supporting Information
Figure S1 Immunochemical characterization of the
specificity of a-syn antibodies utilized for passive
immunotherapy. Immunoblot and immunohistochemical
PLoS ONE | www.plosone.org

Figure S2 Effects of passive immunization with a C-

terminal a-syn antibody on tau. Levels of total and PHF-tau
were examined by immunohistochemistry and immunoblot
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analysis to asses the effects of passive immunization with 9E4. (A,
B) Representative brightfield images of total tau in the frontal
cortex of IgG1- and 9E4-treated non-tg mice, respectively. (C, D)
Representative brightfield images of total tau in the frontal cortex
of IgG1- and 9E4-treated a-syn tg mice, respectively. (E)
Quantitative analysis of total tau levels in the frontal cortex of
IgG1 and 9E4-treated non-tg and a-syn tg mice. (F, G)
Representative brightfield images of PHF-tau in the frontal cortex
of IgG1- and 9E4-treated non-tg mice, respectively. (H, I)
Representative brightfield images of PHF-tau in the frontal cortex
of IgG1- and 9E4-treated a-syn tg mice, respectively. (J)
Quantitative analysis of PHF-tau levels in the frontal cortex of
IgG1 and 9E4-treated non-tg and a-syn tg mice. (K) Immunoblot
of levels of total and PHF-tau in the frontal cortex of IgG1 and
9E4 treated non-tg and a-syn tg mice. (L) Analysis of total tau
levels in the frontal cortex of IgG1 and 9E4-treated non-tg and asyn tg mice as determined by immunoblot. (M) Analysis of PHFtau levels in the frontal cortex of IgG1 and 9E4-treated non-tg and
a-syn tg mice as determined by immunoblot. Scale bar = 40uM.
Error bars represent mean 6 SEM. (*) Indicates p,0.05, when
comparing a-syn tg immunized with IgG1 or 9E4 to IgG1-treated
non-tg mice by one-way ANOVA with post hoc Dunnett’s.
(TIF)

represent mean 6 SEM. (*) indicates p,0.05, when comparing
IgG1-immunized a-syn tg mice to IgG1-imunized non-tg mice by
one-way ANOVA with post hoc Dunnett’s. (#) Indicates p,0.05,
when comparing a-syn tg mice immunized the 9E4 a-syn antibody
to IgG1-treated a-syn tg mice by one-way ANOVA with post hoc
Dunnett’s.
(TIF)
Figure S4 FITC-labeled b-syn crosses the blood-brain
barrier but does not bind neurons in a-syn tg mice. (A, B)
Signal in the FITC channel upon direct visualization of temporal
cortex sections from non-tg and a-syn tg mice injected with FITClabeled b-syn, respectively. (C, D) Representative confocal images
of the neocortex of non-tg and a-syn mice, respectively,
immunolabeled with CSF from mice injected with FITC-labeled
b-syn displaying immunostaining of the neuropil. Scale bar (A-I)
= 10mM.
(TIF)
Figure S5 Further characterization of LC3 immunoreactivity and phagosome involvement of a-syn clearance
in a-syn tg mice immunized with 9E4. (A) a-syn immunoreactivity in a-syn tg mouse immunized with the IgG1 control
antibody. (B) LC3 immunoreactivity in a-syn tg mouse immunized
with the IgG1 control antibody. (C) Co-localization of a-syn and
LC3 immunoreactivity in a-syn tg mouse immunized with the
IgG1 control antibody. (D, G) a-syn immunoreactivity in a-syn tg
mouse immunized with the 9E4 antibody. (E, H) LC3 immunoreactivity in a-syn tg mouse immunized with the 9E4 antibody. (F,
I) Co-localization of a-syn and LC3 immunoreactivity in a-syn tg
mouse immunized with the 9E4 antibody. (J, K) Immuno-gold
electron micrographs of phagosomes from a-syn tg mouse
immunized with the IgG1 control antibody, very few gold particles
were detected. (L, M) Immuno-gold electron microscopy images of
phagosomes from a-syn tg mouse immunized with the 9E4
antibody, abundant gold particles were detected.(N) Quantitative
analysis of gold particles in phagosomes from a-syn tg mice
immunized with either IgG1 control or 9E4 antibody Scale bar (AI) = 10mM (J-M) = 0.5mM Error bars represent mean 6 SEM. (*)
Indicates p,0.05, when comparing IgG1 to 9E4 group by one
way ANOVA with post hoc Dunnet’s.
(TIF)

Figure S3 Effects of passive immunization with a C-

terminal a-syn antibody on vasculature or markers of
glial cell reactivity. (A, B) Representative brightfield images of
the endothelial cells marker Zo-1 immunoreactivity in the frontal
cortex of IgG1- and 9E4-treated non-tg mice, respectively (arrows
indicate location of blood vessels). (C, D) Representative brightfield images of Zo-1 immunoreactivity in the frontal cortex of
IgG1- and 9E4-treated a-syn tg mice, respectively (arrows indicate
location of blood vessels). (E) Analysis of % of Zo-1 immunoreactive neuropil in the frontal cortex of IgG1- and 9E4-treated nontg and a-syn tg mice. (F, G) Representative brightfield images of
the microglial marker Iba-1 immunoreactivity in the frontal cortex
of IgG1- and 9E4-treated non-tg mice, respectively. (G, H)
Representative brightfield images of Iba-1 immunoreactivity in the
frontal cortex of IgG1- and 9E4-treated a-syn tg mice,
respectively. (E) Analysis of Iba-1 immunoreactivity in the frontal
cortex of IgG1- and 9E4-treated non-tg and a-syn tg mice. (F, G)
Representative brightfield images of the microglial marker Iba-1
immunoreactivity in the frontal cortex of IgG1- and 9E4-treated
non-tg mice, respectively. (K, L) Representative brightfield images
of the astroglial cell marker GFAP immunoreactivity in the frontal
cortex of IgG1- and 9E4-treated non-tg mice, respectively (arrows
indicate location of blood vessels). (M, N) Representative brightfield images of GFAP immunoreactivity in the frontal cortex of
IgG1- and 9E4-treated a-syn tg mice, respectively (arrows indicate
location of blood vessels). (E) Analysis of GFAP immunoreactivity
in the frontal cortex of IgG1- and 9E4-treated non-tg and a-syn tg
mice. Scale bar (A-D) = 80uM, (F-N) = 50mM. Error bars
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